PAASP US receives a $1.47M Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop tools to evaluate nonclinical biomedical research quality
The PAASP Network, a global group of independent organizations with a common goal of promoting research quality standards, is thrilled to announce that Network member PAASP US, LLC has been granted a Phase II award through the Small Business Innovation Research (SBIR) program supported by the United States National Institute on Drug Abuse (NIDA) at the NIH. This grant follows a successful Phase I SBIR award and will lead to the development of a robust web application with proprietary analytics supporting project-specific and research unit-specific certification of nonclinical research data quality.
“Robust nonclinical data is an absolute requirement for building an effective translational strategy and developing clinically safe and effective medications,” said Daniel Deaver, Ph.D., CSO of PAASP US and one of the Principal Investigators of the grant. “Most current efforts to facilitate generation of robust nonclinical research data focus on producing guidelines and checklists pertaining to study design and data analysis, but do so mainly from a reporting perspective, rarely consider processes other than study design and data analysis (such as compliance of data records with FAIR principles), and are at risk of triggering normative responses, whereby research teams simply satisfy the guidelines at a time when it is too late to take corrective actions.”
The PAASP US team will work on a novel research evaluation tool – PAASPort® – for early identification of potential risks of bias related to nonclinical research practice. “PAASPort® was created by industry and academic scientists working with business professionals,” said Andre Der-Avakian, Ph.D., COO of PAASP US and the other Principal Investigator of the SBIR award. “It will allow funding organizations such as private investors, non-profit foundations, and corporate and non-corporate VCs to inform both financial (investment) and portfolio (science) decisions by supporting research with low risks of bias, thereby improving the probability that basic nonclinical discoveries will translate into safe and effective clinical treatments.”
During Phase I of the project, the PAASP US team converted an existing paper-and-pencil PAASPort® prototype into a web-based, interactive digital tool. During Phase II, the team will focus on developing and implementing analytical mechanisms to support semi-automated processing of data quality information collected from the online assessment and demonstrating economic benefits of improved nonclinical research practice quality assessments for research investors.
The project will draw on the expertise of a highly motivated and collaborative team of PAASP US employees, advisors and consultants across multiple locations in the US and Europe.
About the PAASP Network
The PAASP Network (Partnership for Assessment and Accreditation of Scientific Practice; www.paasp.net) is an unincorporated association of legally and operationally independent entities (one of which is PAASP US, LLC) acting in different countries, but united in the global goal to promote research quality standards. The Network’s membership includes in vivo and in vitro scientists across several biomedical disciplines, business professionals, and entrepreneurs. As of July 2020, the Network includes members and member organizations in the US, Germany, Benelux, Italy, Russia, Baltic States, and France.
The Small Business Innovation Research (SBIR; www.sbir.gov) program is a highly competitive program that encourages US domestic small businesses to engage in Federal Research/Research and Development (R/R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological potential. By including qualified small businesses in the nation’s R&D arena, high-tech innovation is stimulated and the US gains entrepreneurial spirit as it meets its specific research and development needs.
PAASP US, LLC:
Patricia Kabitzke, Ph.D., CEO
The PAASP Network:
Anton Bespalov, M.D., Ph.D.